title: [Pharmacological prophylaxis of reperfusion syndrome in patients with severe polytrauma accompanied by shock].
abstract: A comparative assessment of buffer activity of reamberin and polyoxyfumaren was made. Their influence on systemic consumption of oxygen, content of lactate in blood, parameters of central hemodynamics were followed. The research includes 44 victims (aged 25-70 years) with severe shockogenic injuries. Reamberin was included in composition of fluid therapy of I group (n=30)and polyoxyfumaren was used in 11 group (n=14). Parameters of acid-base balance of arterial blood, VO2, VCO,, contents of lactate in mixed venous blood, parameters of central hemodynamics were measured in monitor regimen before the infusion. It was proved, that the intravenous infusion of reamberin and polyoxyfumaren accompanied by reliable rise of minute consumption of oxygen (27 and 18% respectively). The drugs decrease the lactate level in blood, reliably increase buffer capacity of blood, correct the metabolic acidosis. Both antihy-poxanthines allow the increase of minute volume of circulation: reamberin on 15%, polyoxyfumaren on 34,9%. The volemic effect of polyoxyfumaren resulted in the increase of circular plasma volume after finishing the infusion on 49,5%, in the case of reamberin - on 16%.
authors.forename: Iu S
authors.initials: IuS
authors.lastname: Polushin
authors.forename: B N
authors.initials: BN
authors.lastname: Shakh
authors.forename: V M
authors.initials: VM
authors.lastname: Teplov
authors.forename: D B
authors.initials: DB
authors.lastname: Smirnov
authors.forename: S S
authors.initials: SS
authors.lastname: Komedev
mesh_terms: D000136:Acid-Base Equilibrium / Q000187:drug effects; D061605:Administration, Intravenous; D000328:Adult; D001802:Blood Substitutes / Q000008:administration & dosage / Q000009:adverse effects; D057186:Comparative Effectiveness Research; D004359:Drug Therapy, Combination; D005260:Female; D005440:Fluid Therapy / Q000379:methods; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008536:Meglumine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects; D015424:Reperfusion / Q000009:adverse effects / Q000379:methods; D015427:Reperfusion Injury / Q000378:metabolism / Q000503:physiopathology / Q000517:prevention & control; D012774:Shock, Traumatic / Q000378:metabolism / Q000503:physiopathology / Q000628:therapy; D013386:Succinates / Q000008:administration & dosage / Q000009:adverse effects; D015599:Trauma Severity Indices; D016896:Treatment Outcome
chemical_list: D001802:Blood Substitutes; C549374:Reamberin; D013386:Succinates; C081207:polyoxydine; D011092:Polyethylene Glycols; D008536:Meglumine